



December 21, 2020  
Vermont Attorney General's Office  
109 State Street  
Montpelier, VT 05609

**RE: New Prescription Drug – 3 Day Notice**

Dear Sir or Madam,

In accordance with 18 V.S.A. § 4637, Myovant Sciences, Inc. provides the following notification of introduction of ORGOVYX™ (relugolix) whose WAC exceeds the threshold set for a specialty drug under the Medicare Part D program:

NDC	PRODUCT	PACKAGE SIZE
72974-120-01	ORGOVYX (relugolix) 120 mg tablets	30 tablets

Please do not hesitate to contact us if you have any questions.

Regards,

DocuSigned by:  
  
C1A1310B2F6D49A...

Daniel Stefureak  
Senior Director Pricing & Contracting  
Myovant Sciences, Inc.

WAC represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to third-party pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates, or reduction in price. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.